Hear the perspective from two prominent breast cancer experts regarding the Oncotype DX test & personalized breast cancer treatment. Each year, more than 200,000 women in the United States are diagnosed with breast cancer.  And a majority of them will be treated with chemotherapy, radiation therapy, surgery or a combination of the three.

But not every woman with early stage breast cancer requires the same treatment. For example, many women undergo chemotherapy with minimal, if any, benefits.

Dr. Marisa Weiss is the Founder and President of breast cancer.org, an online resource of medical and expert information on breast cancer. She is a practicing radiation oncologist at the Lankenau Medical Center in Philadelphia and a breast cancer survivor.

Dr. Ruth Oratz is a Clinical Associate Professor of Medicine at the New York University School of Medicine who specializes in treating women with breast cancer.

One diagnostic tool that is helping physicians and patients determine proper treatment protocols is the Oncotype DX Breast Cancer test.  Developed by Genomic Health, it provides information about an individual breast cancer diagnosis, allowing a woman and her doctor to determine the best treatment approach for her personal tumor type.